|
1
|
Slingerland J and Pagano M: Regulation of
the cdk inhibitor p27 and its deregulation in cancer. J Cell
Physiol. 183:10–17. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Inuzuka H, Gao D, Finley LW, et al:
Acetylation-dependent regulation of Skp2 function. Cell.
150:179–193. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ezoe S, Matsumura I, Nakata S, et al:
GATA-2/estrogen receptor chimera regulates cytokine-dependent
growth of hematopoietic cells through accumulation of p21(WAF1) and
p27(Kip1) proteins. Blood. 100:3512–3520. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Sicari BM, Troxell R, Salim F, Tanwir M,
Takane KK and Fiaschi-Taesch N: c-myc and skp2 coordinate p27
degradation, vascular smooth muscle proliferation, and neointima
formation induced by the parathyroid hormone-related protein.
Endocrinology. 153:861–872. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Dai DM and Zhu H: Expression of P27kip1
and Skp2 in basal cell carcinoma and its clinical pathological
characters. Int Oncol. 38:158–160. 2011.
|
|
6
|
Suzuki S, Fukasawa H, Misaki T, et al: The
amelioration of renal damage in Skp2-deficient mice canceled by
p27kipl deficiency in Skp2-/-p27/-mice. PLoS One. 7:e362492012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nakayama K, Nagahama H, Minamishima YA, et
al: Targeted disruption of Skp2 results in accumulation of cyclin E
and p27(Kip1) polyploidy and centrosome overduplication. EMBO J.
19:2069–2081. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gstaiger M, Jordan R, Lim M, Catzavelos C,
Mestan J, Slingerland J and Krek W: Skp2 is oncogenic and
overexpressed in human cancers. Proc Natl Acad Sci USA.
98:5043–5048. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kudo Y, Kitajima S, Sato S, Miyauchi M,
Ogawa I and Takata T: High expression of S-phase kinase-interacting
protein 2, human F-box protein, correlates with poor prognosis in
oral squamous cell carcinomas. Cancer Res. 61:7044–7047.
2001.PubMed/NCBI
|
|
10
|
Shintani S, Li C, Mihara M, Hino S,
Nakashiro K and Hamakawa H: Skp2 and Jab1 expression are associated
with inverse expression of p27(KIP1) and poor prognosis in oral
squamous cell carcinomas. Oncology. 65:355–362. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong Y, Sui L, Watanabe Y, Sugimoto K and
Tokuda M: S-phase kinase-associated protein 2 expression in
laryngeal squamous cell carcinomas and its prognostic implications.
Oncol Rep. 10:321–325. 2003.PubMed/NCBI
|
|
12
|
Signoretti S, Di Marcotullio L, Richardson
A, et al: Oncogenic role of the ubiquitin ligase subunit Skp2 in
human breast cancer. J Clin Invest. 110:633–641. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Patel SG and Shah JP: TNM staging of
cancers of the head and neck: striving for uniformity among
diversity. CA Cancer J Clin. 55:242–258; quiz 261–262, 264. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang H, Kobayashi R, Galaktionov K and
Beach D: p19Skp1 and p45Skp2 are essential elements of the cyclin
A-CDK2 S phase kinase. Cell. 82:915–925. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Carrano AC, Eytan E, Hershko A and Pagano
M: SKP2 is required for ubiquitin-mediated degradation of the CDK
inhibitor p27. Nat Cell Biol. 1:193–199. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yokoi S, Yasui K, Saito-Ohara F, et al: A
novel target gene, SKP2, within the 5p13 amplicon that is
frequently detected in small cell lung cancers. Am J Pathol.
161:207–216. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Coats S, Flanagan WM, Nourse J and Roberts
JM: Requirement of p27Kip1 for restriction point control of the
fibroblast cell cycle. Science. 272:877–880. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nakatsuka S, Liu A, Yao M, et al:
Methylation of promoter region in p27 gene plays a role in the
development of lymphoid malignancies. Int J Oncol. 22:561–568.
2003.PubMed/NCBI
|
|
19
|
Ewald JA and Jarrard DF: Decreased skp2
expression is necessary but not sufficient for therapy-induced
senescence in prostate cancer. Transl Oncol. 5:278–287. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rose AE, Wang G, Hanniford D, et al:
Clinical relevance of SKP2 alterations in metastatic melanoma.
Pigment Cell Melanoma Res. 24:197–206. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Baresova P, Pitha PM and Lubyova B: Kaposi
sarcoma-associated herpesvirus vIRF-3 protein binds to F-box of
Skp2 protein and acts as a regulator of c-Myc protein function and
stability. J Biol Chem. 287:16199–16208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tschen SI, Georgia S, Dhawan S and Bhushan
A: Skp2 is required for incretin hormone-mediated β-cell
proliferation. Mol Endocrinol. 25:2134–2143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dowen SE, Scott A, Mukherjee G and Stanley
MA: Overexpression of Skp2 in carcinoma of the cervix does not
correlate inversely with p27 expression. Int J Cancer. 105:326–330.
2003. View Article : Google Scholar : PubMed/NCBI
|
